Physician profile
Kenneth D Miller
NPI 1861480535
$24,055.50
in general payments reported to CMS, 2019-2025
28 companies · $4,521 in 2025
The $4,521 reported for 2025 was more than what 81% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,323 · 2020: $2,116 · 2021: $740 · 2022: $6,912 · 2023: $525 · 2024: $918 · 2025: $4,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,431 · Travel and Lodging: $2,075 · Education: $439 · Gift: $19.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,431.10 |
| Travel and Lodging | $2,075.25 |
| Education | $438.74 |
| Gift | $19.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioverativ Therapeutics INC. | $7,728.12 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $6,705.75 | 2022-2024 | Calquence, Imfinzi |
| Onmark, INC. | $3,533.40 | 2025 | |
| Athenex Pharmaceutical Division, LLC | $2,021.72 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $1,100.00 | 2020 | |
| Lilly USA, LLC | $556.38 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Novartis Pharmaceuticals Corporation | $374.52 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $283.26 | 2021-2025 | Opdivo, Opdualag, Augtyro |
| Incyte Corporation | $279.51 | 2022-2025 | Monjuvi, Pemazyre, Zynyz |
| Takeda Pharmaceuticals U.S.A., INC. | $234.37 | 2022-2025 | Iclusig |
| Glaxosmithkline, LLC. | $171.86 | 2023-2025 | Ojjaara, Shingrix |
| Regeneron Healthcare Solutions, INC. | $141.13 | 2023-2025 | Libtayo |
| Janssen Biotech, INC. | $125.68 | 2021-2025 | Rybrevant, Carvykti |
| Abbvie INC. | $123.04 | 2024-2025 | |
| Seagen INC. | $107.60 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $87.42 | 2024-2025 | Keytruda, Welireg, Reblozyl |
| Gilead Sciences, INC. | $85.23 | 2021-2025 | Trodelvy |
| Pfizer INC. | $75.95 | 2021-2025 | |
| Exelixis INC. | $68.15 | 2024 | Cabometyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.61 | 2021-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $46.60 | 2022-2023 | Epkinly, Imbruvica |
| Stemline Therapeutics INC. | $32.69 | 2023 | Orserdu |
| Eisai INC. | $27.73 | 2024 | |
| Genzyme Corporation | $23.69 | 2019 | |
| Rigel Pharmaceuticals, INC. | $22.04 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Emd Serono, INC. | $19.29 | 2019 | |
| Exact Sciences Corporation | $17.20 | 2025 | Cologuard Collection Kit |
| Apellis Pharmaceuticals, INC. | $15.56 | 2023 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.